Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Breakfast News - First laboratory-grown human-skin test service, to use artifical intelligence, to provide clinical validation for cosmetic, personal hygiene and skin care products

Breakfast News -  First laboratory-grown human-skin test service, to use artifical intelligence, to provide clinical validation for cosmetic, personal hygiene and skin care products

First laboratory-grown human-skin test service, to use artifical intelligence, to provide clinical validation for cosmetic, personal hygiene and skin care products.

Labskin (Innovenn Ltd.), a wholly-owned subsidiary of Integumen plc., (AIM:SKIN) today announces that it has entered into a partnership with RinoLab (www.rinolab.com) to provide Labskin clients with access to an AI machine learning platform which accelerates development of cosmetics, skincare, woundcare, personal hygiene and pharmaceutical topical drug delivery products, and does not require animal testing. The service is expected to go live in Q4, 2018.

 

Labskin has also entered into a partnership agreement with AIM quoted Venn Life Sciences Holdings plc ("Venn") to integrate clinical validation protocols into Labskin AI. This will provide certified "Clinically Tested"product claim services to brand owners and producers of most skin care products. - see related party transaction detail below.  

 

Labskin AI is an AI based laboratory-grown human-skin testing platform. It uses clinical trial test protocols and datasets, eliminating the need for animal testing completely for the development of all skin care products. The AI platform and physical Labskin laboratories offers clients an online end to end skin care product validation system, tested on laboratory grown human skin.

 

Due to the recent increase in demand for Labskin services, additional laboratory development support services are being provided through an agreement signed with Sheffield Hallam University, UK.

 

Gerard Brandon (CEO of Integumen plc and Director of Innovenn Ltd) commented:

"We are delighted to announce this collaboration of technologies and work with the skills and expertise of the RinoLab Team on the Labskin AI platform. Partnering with Venn Life Sciences and their clinical research organisation raises the bar for manufacturers of skin care products in quality control for consumer product information file (PIF) verification. Sheffield Hallam University has worked with Innovenn for many years in multiple Labskin development projects and extends the reach of our development services for our clients. Labskin has successfully moved from selling Labskin equipment supplies to being a fully fledged service provider during H2 2018, increasing our orders by 350% over H1. I believe that Labskin AI is now the ultimate go-to-market service for skin care product development, comprising formulation efficacy, testing and certification for EU and US consumer product launches."

Tony Richardson (CEO Venn Life Sciences Holdings plc) commented:

"This is an exciting development and extends our pharmaceutical clinical validation approach to the consumer health, personal and skin care industries in a way that has never been done before. We see multiple opportunities for cross selling of services to the same clients of both Venn and Labskin, not least the new services of topical drug delivery and drug metabolism through the skin. By partnering with Labskin and RinoLab using the AI platform we look forward to being able to offer a unique certification service to Labskin clients, as well as extend AI machine learning data analysis across our CRO service to pharmaceutical clients, helping them reduce their overall development costs by getting their products to the market faster."

Fin Murray (CEO of RinoCloud Ltd - RinoLab) commented:

"The RinoLab Team have developed a range of algorithms for the dissimination of big data specifically from scientific sources and is perfectly suited to analysing Labskin data to unlock trends and patterns that would normally be missed on a manual review. Using RinoLab, Labskin AI clients are provided with suggested alterations to improve product formulations to increase efficiency and efficacy. RinoLab analysis provides supporting data for the "Product Information File" required by cosmetic brand and skin care companies, prior to product launches in the US and EU markets.

 

Collaboration partners

Labskin (Innovenn Ltd - Integumen plc)

Laboratory grown human skin testing services. Specifically developed to host harmful bacteria on simulated human skin. It is the best testing platform for antimicrobial products, such as anti-dandruff shampoos and anti-acne creams, anti-aging, anti-fungal, UV sun exposure, toxic shock, and drug delivery through the skin, which cannot currently be carried out in vivo (animal models) due to ethical constraints of testing harmful bacteria.

RinoLab (RinoCloud Ltd)

www.rinolab.com

Rinolab is a set of software tools that ingests data from any source, in any format, interacts with it, learns from it and enrichs it to unlock insights and discoveries. RinoLab is developed by Rinocloud Ltd, a company focused on delivering big data type functionality, AI functionality and world class data management infrastructure.

Venn Life Sciences Holdings plc

Drug Development Partner

Venn Life Sciences Holdings plc is an Integrated Drug Development Partner offering a unique combination of drug development expertise, clinical trial design and execution services. With more than 170 professionals Venn creates, plans and executes drug and medical device development programs effectively and seamlessly for their pharmaceutical manufacturing clients. With dedicated operations in Ireland, France, Germany, the Netherlands, the UK, the US, and Europe-wide representation.

 

Related party transaction

Venn owns 16.03% of the current issued share capital of the Company, and is a "substantial shareholder" in the Company, and therefore a related party under the AIM Rules for Companies ("AIM Rules").

Entering into the agreement with a related party, as referred to above, constitutes a related party transaction under the AIM Rules. The terms of the agreement have been agreed by Innovenn and Venn, who are providing test validation protocols in exchange for a fixed percentage of new revenues.

Tony Richardson, the Chairman of Integumen, is also a director of Venn and is not an independent director for the purpose of considering the agreement referred to above in line with AIM Rule 13. Mr Richardson has therefore not taken part in the Board's deliberations concerning the terms of the partnership agreement. The independent directors, (being all the other directors of Integeumen, with the exception of Mr Richardson) have considered the terms of the partnership agreement. Having consulted with SPARK Advisory Partners Limited, the Company's nominated adviser, the independent directors consider that the terms of the partnership agreement are fair and reasonable insofar as Shareholders are concerned.

 

 

Integumen plc

Innovenn Ltd. (Labskin)

Gerard Brandon, CEO

Director

+353 85 109 1457  

SPARK Advisory Partners Limited (Nominated Adviser)

 

Neil Baldwin

Andrew Emmott

+44 (0) 113 370 8974

Hybridan LLP  (Broker)

Claire Noyce

+44 (0) 20 3764 2341

 

 

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use